nach oben

Erschienen in:

03.01.2019 | NON-THEMATIC REVIEW

MACC1—the first decade of a key metastasis molecule from gene discovery to clinical translation

verfasst von: Harikrishnan Radhakrishnan, Wolfgang Walther, Fabian Zincke, Dennis Kobelt, Francesca Imbastari, Müge Erdem, Benedikt Kortüm, Mathias Dahlmann, Ulrike Stein

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Deciphering the paths to metastasis and identifying key molecules driving this process is one important issue for understanding and treatment of cancer. Such a key driver molecule is Metastasis Associated in Colon Cancer 1 (MACC1). A decade long research on this evolutionarily conserved molecule with features of a transcription factor as well as an adapter protein for versatile protein-protein interactions has shown that it has manifold properties driving tumors to their metastatic stage. MACC1 transcriptionally regulates genes involved in epithelial-mesenchymal transition (EMT), including those which are able to directly induce metastasis like c-MET, impacts tumor cell migration and invasion, and induces metastasis in solid cancers. MACC1 has proven as a valuable biomarker for prognosis of metastasis formation linked to patient survival and gives promise to also act as a predictive marker for individualized therapies in a broad variety of cancers. This review discusses the many features of MACC1 in the context of the hallmarks of cancer and the potential of this molecule as biomarker and novel therapeutic target for restriction and prevention of metastasis.

Stein, U., & Schlag, P. M. (2007). Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 176, 61–80.PubMed

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21492.

Goldberg, R. M., Rothenberg, M. L., Van Cutsem, E., Benson, A. B., 3rd, Blanke, C. D., Diasio, R. B., et al. (2007). The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist, 12(1), 38–50. https://doi.org/10.1634/theoncologist.12-1-38.CrossRefPubMed

Stein, U., Walther, W., Arlt, F., Schwabe, H., Smith, J., Fichtner, I., et al. (2008). MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nature Medicine, 15, 59. https://doi.org/10.1038/nm.1889.CrossRefPubMed

Stein, U., Dahlmann, M., & Walther, W. (2010). MACC1 - more than metastasis? Facts and predictions about a novel gene. J Mol Med (Berl), 88(1), 11–18. https://doi.org/10.1007/s00109-009-0537-1.CrossRef

Stein, U. (2013). MACC1 - a novel target for solid cancers. Expert Opinion on Therapeutic Targets, 17(9), 1039–1052. https://doi.org/10.1517/14728222.2013.815727.CrossRefPubMed

Zlobec, I. (2013). Novel biomarkers for the prediction of metastasis in colorectal cancer. Expert Opinion on Medical Diagnostics, 7, 137–146. https://doi.org/10.1517/17530059.2013.753054.CrossRefPubMed

Weidle, U. H., Birzele, F., & Kruger, A. (2015). Molecular targets and pathways involved in liver metastasis of colorectal cancer. Clinical & Experimental Metastasis, 32(6), 623–635. https://doi.org/10.1007/s10585-015-9732-3.CrossRef

Kopczyńska, E. K. (2016). The potential therapeutic applications and prognostic significance of metastasis associated in colon cancer 1 (MACC1) in cancers. Współczesna Onkologia, 4, 273–280. https://doi.org/10.5114/wo.2016.61846.CrossRef

10.

Wu, Z.-Z., Chen, L.-S., Zhou, R., Bin, J.-P., Liao, Y.-L., & Liao, W.-J. (2016). Metastasis-associated in colon cancer-1 in gastric cancer: beyond metastasis. World Journal of Gastroenterology, 22, 6629. https://doi.org/10.3748/wjg.v22.i29.6629.CrossRefPubMedPubMedCentral

11.

Mudduluru, G., Ilm, K., Dahlmann, M., & Stein, U. (2017). MACC1, a novel player in solid cancer carcinogenesis. In Mechanisms of molecular carcinogenesis – volume 1 (pp. 11–38). Cham: Springer International Publishing.CrossRef

12.

Wang, G., Fu, Z., & Li, D. (2015). MACC1 overexpression and survival in solid tumors: a meta-analysis. Tumour Biology, 36(2), 1055–1065. https://doi.org/10.1007/s13277-014-2736-9.CrossRefPubMed

13.

Wu, Z., Zhou, R., Su, Y., Sun, L., Liao, Y., & Liao, W. (2015). Prognostic value of MACC1 in digestive system neoplasms: a systematic review and meta-analysis. BioMed Research International, 2015, 252043. https://doi.org/10.1155/2015/252043.CrossRefPubMedPubMedCentral

14.

Sun, D.-W., Zhang, Y.-Y., Qi, Y., Liu, G.-Q., Chen, Y.-G., Ma, J., et al. (2015). Prognostic and clinicopathological significance of MACC1 expression in hepatocellular carcinoma patients: a meta-analysis. International Journal of Clinical and Experimental Medicine, 8, 4769–4777.PubMedPubMedCentral

15.

Zhao, Y., Dai, C., Wang, M., Kang, H., Lin, S., Yang, P., et al. (2016). Clinicopathological and prognostic significance of metastasis-associated in colon cancer-1 (MACC1) overexpression in colorectal cancer: a meta-analysis. Oncotarget, 7(39), 62966–62975. https://doi.org/10.18632/oncotarget.11287.CrossRefPubMedPubMedCentral

16.

Stein, U., Burock, S., Herrmann, P., Wendler, I., Niederstrasser, M., Wernecke, K.-D., et al. (2012). Circulating MACC1 Transcripts in Colorectal Cancer Patient Plasma Predict Metastasis and Prognosis. PLoS ONE, 7(11), e49249. https://doi.org/10.1371/journal.pone.0049249.CrossRefPubMedPubMedCentral

17.

Wang, G., Kang, M. X., Lu, W. J., Chen, Y., Zhang, B., & Wu, Y. L. (2012). MACC1: A potential molecule associated with pancreatic cancer metastasis and chemoresistance. Oncology Letters, 4(4), 783–791. https://doi.org/10.3892/ol.2012.784.CrossRefPubMedPubMedCentral

18.

Burock, S., Herrmann, P., Wendler, I., Niederstrasser, M., Wernecke, K.-D., & Stein, U. (2015). Circulating metastasis associated in colon cancer 1 transcripts in gastric cancer patient plasma as diagnostic and prognostic biomarker. World Journal of Gastroenterology, 21, 333. https://doi.org/10.3748/wjg.v21.i1.333.CrossRefPubMedPubMedCentral

19.

Wang, Z., Cai, M., Weng, Y., Zhang, F., Meng, D., Song, J., et al. (2015). Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer. Journal of Cancer Research and Clinical Oncology, 141(8), 1353–1361. https://doi.org/10.1007/s00432-014-1903-0.CrossRefPubMed

20.

Tan, W., Xie, X., Li, L., Tang, H., Ye, X., Chen, L., et al. (2016). Diagnostic and prognostic value of serum MACC1 in breast cancer patients. Oncotarget, 7(51), 84408–84415. https://doi.org/10.18632/oncotarget.12910.CrossRefPubMedPubMedCentral

21.

Ashktorab, H., Hermann, P., Nouraie, M., Shokrani, B., Lee, E., Haidary, T., et al. (2016). Increased MACC1 levels in tissues and blood identify colon adenoma patients at high risk. Journal of Translational Medicine, 14(1), 215. https://doi.org/10.1186/s12967-016-0971-0.CrossRefPubMedPubMedCentral

22.

Shimokawa, H., Uramoto, H., Onitsuka, T., Chundong, G., Hanagiri, T., Oyama, T., et al. (2011). Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. The Journal of Thoracic and Cardiovascular Surgery, 141, 895–898. https://doi.org/10.1016/j.jtcvs.2010.09.044.CrossRefPubMed

23.

Isella, C., Mellano, A., Galimi, F., Petti, C., Capussotti, L., De Simone, M., et al. (2013). MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Annals of Surgery, 257, 1089–1095. https://doi.org/10.1097/SLA.0b013e31828f96bc.CrossRefPubMed

24.

Gao, S., Lin, B.-Y., Yang, Z., Zheng, Z.-Y., Liu, Z.-K., Wu, L.-M., et al. (2014). Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation. International Journal of Medical Sciences, 11, 268–275. https://doi.org/10.7150/ijms.7769.CrossRefPubMedPubMedCentral

25.

Li, H. F., Liu, Y. Q., Shen, Z. J., Gan, X. F., Han, J. J., Liu, Y. Y., et al. (2015). Downregulation of MACC1 inhibits invasion, migration and proliferation, attenuates cisplatin resistance and induces apoptosis in tongue squamous cell carcinoma. Oncology Reports, 33(2), 651–660. https://doi.org/10.3892/or.2014.3612.CrossRefPubMed

26.

Shang, C., Hong, Y., Guo, Y., Liu, Y. H., & Xue, Y. X. (2015). Influence of the MACC1 gene on sensitivity to chemotherapy in human U251 glioblastoma cells. Asian Pacific Journal of Cancer Prevention, 16(1), 195–199. https://doi.org/10.7314/APJCP.2015.16.1.195.CrossRefPubMed

27.

Chen, Z. M., Shi, H. R., Li, X., Deng, Y. X., & Zhang, R. T. (2015). Downregulation of MACC1 expression enhances cisplatin sensitivity in SKOV-3/DDP cells. Genetics and Molecular Research, 14, 17134–17144. https://doi.org/10.4238/2015.December.16.13.CrossRefPubMed

28.

Zhang, R., Shi, H., Ren, F., Li, X., Zhang, M., Feng, W., et al. (2016). Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells. Oncology Reports, 35(4), 2466–2472. https://doi.org/10.3892/or.2016.4585.CrossRefPubMed

29.

Wang, C., Wen, Z., Xie, J., Zhao, Y., Zhao, L., Zhang, S., et al. (2017). MACC1 mediates chemotherapy sensitivity of 5-FU and cisplatin via regulating MCT1 expression in gastric cancer. Biochemical and Biophysical Research Communications, 485(3), 665–671. https://doi.org/10.1016/j.bbrc.2017.02.096.CrossRefPubMed

30.

Zhang, Q., Zhang, B., Sun, L., Yan, Q., Zhang, Y., Zhang, Z., et al. (2018). Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation. Acta Biochimica et Biophysica Sinica Shanghai, 50(8), 748–756. https://doi.org/10.1093/abbs/gmy074.CrossRef

31.

Duan, J., Chen, L., Zhou, M., Zhang, J., Sun, L., Huang, N., et al. (2017). MACC1 decreases the chemosensitivity of gastric cancer cells to oxaliplatin by regulating FASN expression. Oncology Reports, 37, 2583–2592. https://doi.org/10.3892/or.2017.5519.CrossRefPubMedPubMedCentral

32.

Wang, J., Wang, W., Cai, H., Du, B., Zhang, L., Ma, W., et al. (2017). MACC1 facilitates chemoresistance and cancer stem celllike properties of colon cancer cells through the PI3K/AKT signaling pathway. Molecular Medicine Reports, 16(6), 8747–8754. https://doi.org/10.3892/mmr.2017.7721.CrossRefPubMedPubMedCentral

33.

Rohr, U. P., Herrmann, P., Ilm, K., Zhang, H., Lohmann, S., Reiser, A., et al. (2017). Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies. Annals of Oncology, 28(8), 1869–1875. https://doi.org/10.1093/annonc/mdx207.CrossRefPubMed

34.

Zhou, W., Liu, L., Xue, Y., Zheng, J., Liu, X., Ma, J., et al. (2017). Combination of endothelial-monocyte-activating polypeptide-II with temozolomide suppress malignant biological behaviors of human glioblastoma stem cells via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signal pathway. Frontiers in Molecular Neuroscience, 10, 68. https://doi.org/10.3389/fnmol.2017.00068.CrossRefPubMedPubMedCentral

35.

Kawamura, M., Saigusa, S., Toiyama, Y., Tanaka, K., Okugawa, Y., Hiro, J., et al. (2012). Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Research, 32(4), 1527–1531.PubMed

36.

Yang, Y. P., Qu, J. H., Chang, X. J., Lu, Y. Y., Bai, W. L., Dong, Z., et al. (2013). High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. Journal of Translational Medicine, 11, 41. https://doi.org/10.1186/1479-5876-11-41.CrossRefPubMedPubMedCentral

37.

Zerbino, D. R., Achuthan, P., Akanni, W., Amode, M. R., Barrell, D., Bhai, J., et al. (2018). Ensembl 2018. Nucleic Acids Research, 46(D1), D754–D761. https://doi.org/10.1093/nar/gkx1098.CrossRefPubMed

38.

Zhao, Y., Liu, Y., Lin, L., Huang, Q., He, W., Zhang, S., et al. (2018). The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1. Molecular Cancer, 17(1), 69. https://doi.org/10.1186/s12943-018-0820-2.CrossRefPubMedPubMedCentral

39.

Thierry-Mieg, D., & Thierry-Mieg, J. (2006). AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biology, 7(Suppl 1, S12), 11–14. https://doi.org/10.1186/gb-2006-7-s1-s12.CrossRef

40.

Kokoszyńska, K., Kryński, J., Rychlewski, L., & Wyrwicz, L. S. (2009). Unexpected domain composition of MACC1 links MET signaling and apoptosis. Acta Biochimica Polonica, 56, 317–323.CrossRef

41.

Juneja, M., Ilm, K., Schlag, P. M., & Stein, U. (2013). Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer. Molecular Oncology, 7, 929–943. https://doi.org/10.1016/j.molonc.2013.05.003.CrossRefPubMedPubMedCentral

42.

Guo, T., Zhao, S., Wang, P., Xue, X., Zhang, Y., Yang, M., et al. (2017). YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma. Oncotarget, 8, 48110–48125. https://doi.org/10.18632/oncotarget.18262.CrossRefPubMedPubMedCentral

43.

Xia, J., Wang, H., Huang, H., Sun, L., Dong, S., Huang, N., et al. (2016). Elevated Orai1 and STIM1 expressions upregulate MACC1 expression to promote tumor cell proliferation, metabolism, migration, and invasion in human gastric cancer. Cancer Letters, 381, 31–40. https://doi.org/10.1016/j.canlet.2016.07.014.CrossRefPubMed

44.

Montorsi, L., Guizzetti, F., Alecci, C., Caporali, A., Martello, A., Atene, C. G., et al. (2016). Loss of ZFP36 expression in colorectal cancer correlates to wnt/ ss-catenin activity and enhances epithelial-to-mesenchymal transition through upregulation of ZEB1, SOX9 and MACC1. Oncotarget, 7(37), 59144–59157. https://doi.org/10.18632/oncotarget.10828.CrossRefPubMedPubMedCentral

45.

Li, S., Zhu, J., Li, J., Li, S., & Li, B. (2018). MicroRNA-141 inhibits proliferation of gastric cardia adenocarcinoma by targeting MACC1. Archives of Medical Science, 14, 588–596. https://doi.org/10.5114/aoms.2017.68757.CrossRefPubMed

46.

Zhang, Y., Wang, Z., Chen, M., Peng, L., Wang, X., Ma, Q., et al. (2012). MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Molecular Cancer, 11, 23. https://doi.org/10.1186/1476-4598-11-23.CrossRefPubMedPubMedCentral

47.

Tokarz, P., & Blasiak, J. (2012). The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochimica Polonica, 59, 467–474.CrossRef

48.

Wang, G., Gu, J., & Gao, Y. (2016). MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer. Tumour Biology, 37(10), 13983–13993. https://doi.org/10.1007/s13277-016-5252-2.CrossRefPubMed

49.

Feng, J., Wang, J., Chen, M., Chen, G., Wu, Z., Ying, L., et al. (2015). miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma. Oncology Reports, 33(2), 713–720. https://doi.org/10.3892/or.2014.3642.CrossRefPubMed

50.

Ilm, K., Fuchs, S., Mudduluru, G., & Stein, U. (2016). MACC1 is post-transcriptionally regulated by miR-218 in colorectal cancer. Oncotarget, 7(33), 53443–53458. https://doi.org/10.18632/oncotarget.10803.CrossRefPubMedPubMedCentral

51.

Huang, N., Wu, Z., Lin, L., Zhou, M., Wang, L., Ma, H., et al. (2015). MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget, 6(17), 15222–15234. https://doi.org/10.18632/oncotarget.3835.CrossRefPubMedPubMedCentral

52.

Zhang, T., Liu, W., Zeng, X.-c., Jiang, N., Fu, B.-s., Guo, Y., et al. (2016). Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma. Biomedicine & Pharmacotherapy, 84, 583–591. https://doi.org/10.1016/J.BIOPHA.2016.09.056.CrossRef

53.

Shang, C., Hong, Y., Guo, Y., & Xue, Y. X. (2016). Mir-338-3p inhibits malignant biological behaviors of glioma cells by targeting MACC1 gene. Medical Science Monitor, 22, 710–716. https://doi.org/10.12659/MSM.897055.CrossRefPubMedPubMedCentral

54.

Hua, F.-F., Liu, S.-S., Zhu, L.-H., Wang, Y.-H., Liang, X., Ma, N., et al. (2017). MiRNA-338-3p regulates cervical cancer cells proliferation by targeting MACC1 through MAPK signaling pathway. European Review for Medical and Pharmacological Sciences, 21, 5342–5352.PubMed

55.

Li, J., Mao, X., Wang, X., Miao, G., & Li, J. (2017). miR-433 reduces cell viability and promotes cell apoptosis by regulating MACC1 in colorectal cancer. Oncology Letters, 13(1), 81–88. https://doi.org/10.3892/ol.2016.5445.CrossRefPubMed

56.

Wang, S., Zhang, Y., Yuan, S., & Ji, X. (2018). MicroRNA485 targets MACC1 and inhibits cervical cancer cell proliferation and invasion. Molecular Medicine Reports, 18(2), 2407–2416. https://doi.org/10.3892/mmr.2018.9186.CrossRefPubMed

57.

Ma, L., Zhou, Y., Luo, X., Gao, H., Deng, X., & Jiang, Y. (2017). Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer. Oncotarget, 8(3), 4125–4135. https://doi.org/10.18632/oncotarget.13670.CrossRefPubMed

58.

Cui, Z., Tang, J., Chen, J., & Wang, Z. (2014). Hsa-miR-574-5p negatively regulates MACC-1 expression to suppress colorectal cancer liver metastasis. Cancer Cell International, 14, 47. https://doi.org/10.1186/1475-2867-14-47.CrossRefPubMedPubMedCentral

59.

Wang, N., Zhang, Y., & Liang, H. (2018). microRNA-598 inhibits cell proliferation and invasion of glioblastoma by directly targeting metastasis associated in colon cancer-1. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. https://doi.org/10.3727/096504018X15185735627746.

60.

Pan, T., Chen, W., Yuan, X., Shen, J., Qin, C., & Wang, L. (2017). miR-944 inhibits metastasis of gastric cancer by preventing the epithelial-mesenchymal transition via MACC1/Met/AKT signaling. FEBS Open Bio, 7(7), 905–914. https://doi.org/10.1002/2211-5463.12215.CrossRefPubMedPubMedCentral

61.

Wen, L., Li, Y., Jiang, Z., Zhang, Y., Yang, B., & Han, F. (2017). miR-944 inhibits cell migration and invasion by targeting MACC1 in colorectal cancer. Oncology Reports, 37(6), 3415–3422. https://doi.org/10.3892/or.2017.5611.CrossRefPubMed

62.

Tokarz, P., Pawlowska, E., Bialkowska-Warzecha, J., & Blasiak, J. (2017). The significance of DNA methylation profile in metastasis-related genes for the progression of colorectal cancer. Cellular and Molecular Biology (Noisy-le-Grand, France), 63, 79–87.CrossRef

63.

Li, Z., Yanfang, W., Li, J., Jiang, P., Peng, T., Chen, K., et al. (2018). Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer. Cancer Letters, 432, 237–250. https://doi.org/10.1016/j.canlet.2018.04.035.CrossRefPubMed

64.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70. https://doi.org/10.1016/S0092-8674(00)81683-9.CrossRef

65.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

66.

Nitsche, U., Rosenberg, R., Balmert, A., Schuster, T., Slotta-Huspenina, J., Herrmann, P., et al. (2012). Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Annals of Surgery, 256(5), 763–771; discussion 771. https://doi.org/10.1097/SLA.0b013e318272de87.CrossRefPubMed

67.

Shirahata, A., Sakata, M., Kitamura, Y., Sakuraba, K., Yokomizo, K., Goto, T., et al. (2010). MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Research, 30(9), 3441–3444.PubMed

68.

Wang, Z., Li, Z., Wu, C., Wang, Y., Xia, Y., Chen, L., et al. (2014). MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer. Medical Oncology, 31(1), 790. https://doi.org/10.1007/s12032-013-0790-6.CrossRefPubMed

69.

Qiu, J., Huang, P., Liu, Q., Hong, J., Li, B., Lu, C., et al. (2011). Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. Journal of Translational Medicine, 9, 166. https://doi.org/10.1186/1479-5876-9-166.CrossRefPubMedPubMedCentral

70.

Xie, C., Wu, J., Yun, J., Lai, J., Yuan, Y., Gao, Z., et al. (2013). MACC1 as a prognostic biomarker for early-stage and AFP-normal hepatocellular carcinoma. PLoS ONE, 8(5), e64235. https://doi.org/10.1371/journal.pone.0064235.CrossRefPubMedPubMedCentral

71.

Huang, Y., Zhang, H., Cai, J., Fang, L., Wu, J., Ye, C., et al. (2013). Overexpression of MACC1 and Its significance in human Breast Cancer Progression. Cell & Bioscience, 3(1), 16. https://doi.org/10.1186/2045-3701-3-16.CrossRef

72.

Muendlein, A., Hubalek, M., Geller-Rhomberg, S., Gasser, K., Winder, T., Drexel, H., et al. (2014). Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients. European Journal of Cancer, 50(12), 2134–2141. https://doi.org/10.1016/j.ejca.2014.05.007.CrossRefPubMed

73.

Hu, H., Tian, D., Chen, T., Han, R., Sun, Y., & Wu, C. (2014). Metastasis-associated in colon cancer 1 is a novel survival-related biomarker for human patients with renal pelvis carcinoma. PLoS ONE, 9(6), e100161. https://doi.org/10.1371/journal.pone.0100161.CrossRefPubMedPubMedCentral

74.

Lederer, A., Herrmann, P., Seehofer, D., Dietel, M., Pratschke, J., Schlag, P., et al. (2015). Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients. Hepatology, 62(3), 841–850. https://doi.org/10.1002/hep.27885.CrossRefPubMed

75.

Li, H., Zhang, H., Zhao, S., Shi, Y., Yao, J., Zhang, Y., et al. (2015). Overexpression of MACC1 and the association with hepatocyte growth factor/c-Met in epithelial ovarian cancer. Oncology Letters, 9(5), 1989–1996. https://doi.org/10.3892/ol.2015.2984.CrossRefPubMedPubMedCentral

76.

Zhou, X., Xu, C.-J., Wang, J.-X., Dai, T., Ye, Y.-P., Cui, Y.-M., et al. (2015). Metastasis-associated in colon cancer-1 associates With poor prognosis and promotes cell invasion and angiogenesis in human cervical cancer. International Journal of Gynecological Cancer, 25, 1353–1363. https://doi.org/10.1097/IGC.0000000000000524.CrossRefPubMedPubMedCentral

77.

Hagemann, C., Fuchs, S., Monoranu, C. M., Herrmann, P., Smith, J., Hohmann, T., et al. (2013). Impact of MACC1 on human malignant glioma progression and patients unfavorable prognosis. Neuro-Oncology, 15(12), 1696–1709. https://doi.org/10.1093/neuonc/not136.CrossRefPubMedPubMedCentral

78.

Yang, T., Kong, B., Kuang, Y. Q., Cheng, L., Gu, J. W., Zhang, J. H., et al. (2014). Overexpression of MACC1 protein and its clinical implications in patients with glioma. Tumour Biology, 35(1), 815–819. https://doi.org/10.1007/s13277-013-1112-5.CrossRefPubMed

79.

Zhang, K., Tian, F., Zhang, Y., Zhu, Q., Xue, N., Zhu, H., et al. (2014). MACC1 is involved in the regulation of proliferation, colony formation, invasion ability, cell cycle distribution, apoptosis and tumorigenicity by altering Akt signaling pathway in human osteosarcoma. Tumour Biology, 35(3), 2537–2548. https://doi.org/10.1007/s13277-013-1335-5.CrossRefPubMed

80.

Koelzer, V. H., Herrmann, P., Zlobec, I., Karamitopoulou, E., Lugli, A., & Stein, U. (2015). Heterogeneity analysis of metastasis associated in colon cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study. BMC Cancer, 15, 160. https://doi.org/10.1186/s12885-015-1150-z.CrossRefPubMedPubMedCentral

81.

Barbazan, J., Dunkel, Y., Li, H., Nitsche, U., Janssen, K. P., Messer, K., et al. (2016). Prognostic impact of modulators of G proteins in circulating tumor cells from patients with metastatic colorectal cancer. Scientific Reports, 6, 22112. https://doi.org/10.1038/srep22112.CrossRefPubMedPubMedCentral

82.

Lemos, C., Hardt, M. S., Juneja, M., Voss, C., Forster, S., Jerchow, B., et al. (2016). MACC1 induces tumor progression in transgenic mice and colorectal cancer patients via increased pluripotency markers Nanog and Oct4. Clinical Cancer Research, 22(11), 2812–2824. https://doi.org/10.1158/1078-0432.CCR-15-1425.CrossRefPubMed

83.

Jiang, W. G., Sanders, A. J., Katoh, M., Ungefroren, H., Gieseler, F., Prince, M., et al. (2015). Tissue invasion and metastasis: molecular, biological and clinical perspectives. Seminars in Cancer Biology, 35, S244–S275. https://doi.org/10.1016/j.semcancer.2015.03.008.CrossRefPubMed

84.

Pichorner, A., Sack, U., Kobelt, D., Kelch, I., Arlt, F., Smith, J., et al. (2012). In vivo imaging of colorectal cancer growth and metastasis by targeting MACC1 with shRNA in xenografted mice. Clinical & Experimental Metastasis, 29(6), 573–583. https://doi.org/10.1007/s10585-012-9472-6.CrossRef

85.

Stein, U., Smith, J., Walther, W., & Arlt, F. (2009). MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle, 8(15), 2467–2469. https://doi.org/10.4161/cc.8.15.9018.CrossRefPubMed

86.

Zhang, R., Shi, H., Chen, Z., Wu, Q., Ren, F., & Huang, H. (2011). Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. Journal of Experimental & Clinical Cancer Research, 30, 83. https://doi.org/10.1186/1756-9966-30-83.CrossRef

87.

Sheng, X. J., Li, Z., Sun, M., Wang, Z. H., Zhou, D. M., Li, J. Q., et al. (2014). MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor c-MET. Oncology Letters, 8(2), 891–897. https://doi.org/10.3892/ol.2014.2184.CrossRefPubMedPubMedCentral

88.

Sun, L., Duan, J., Jiang, Y., Wang, L., Huang, N., Lin, L., et al. (2015). Metastasis-associated in colon cancer-1 upregulates vascular endothelial growth factor-C/D to promote lymphangiogenesis in human gastric cancer. Cancer Letters, 357, 242–253. https://doi.org/10.1016/j.canlet.2014.11.035.CrossRefPubMed

89.

Gao, J., Ding, F., Liu, Q., & Yao, Y. (2013). Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Molecular and Cellular Biochemistry, 376(1-2), 21–32. https://doi.org/10.1007/s11010-012-1545-y.CrossRefPubMed

90.

Wang, L., Lin, L., Chen, X., Sun, L., Liao, Y., Huang, N., et al. (2015). Metastasis-associated in colon cancer-1 promotes vasculogenic mimicry in gastric cancer by upregulating TWIST1/2. Oncotarget, 6(13), 11492–11506. https://doi.org/10.18632/oncotarget.3416.CrossRefPubMedPubMedCentral

91.

Wang, L., Zhou, R., Zhao, Y., Dong, S., Zhang, J., Luo, Y., et al. (2016). MACC-1 promotes endothelium-dependent angiogenesis in gastric cancer by activating TWIST1/VEGF-a signal pathway. PLoS ONE, 11(6), e0157137. https://doi.org/10.1371/journal.pone.0157137.CrossRefPubMedPubMedCentral

92.

Meng, F., Li, H., Shi, H., Yang, Q., Zhang, F., Yang, Y., et al. (2013). MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/beta-catenin signaling pathway. PLoS ONE, 8(4), e60821. https://doi.org/10.1371/journal.pone.0060821.CrossRefPubMedPubMedCentral

93.

Zhen, T., Dai, S., Li, H., Yang, Y., Kang, L., Shi, H., et al. (2014). MACC1 promotes carcinogenesis of colorectal cancer via beta-catenin signaling pathway. Oncotarget, 5(11), 3756–3769. https://doi.org/10.18632/oncotarget.1993.CrossRefPubMedPubMedCentral

94.

Chen, S., Zong, Z. H., Wu, D. D., Sun, K. X., Liu, B. L., & Zhao, Y. (2017). The role of metastasis-associated in colon cancer 1 (MACC1) in endometrial carcinoma tumorigenesis and progression. Molecular Carcinogenesis, 56(4), 1361–1371. https://doi.org/10.1002/mc.22599.CrossRefPubMed

95.

Ding, Y., Li, X., Hong, D., Jiang, L., He, Y., & Fang, H. (2016). Silence of MACC1 decreases cell migration and invasion in human malignant melanoma through inhibiting the EMT. Bioscience Trends, 10(4), 258–264. https://doi.org/10.5582/bst.2016.01091.CrossRefPubMed

96.

Qian, L. Q., Li, X. Q., Ye, P. H., Su, H. Y., Wang, G., Liu, Y., et al. (2017). Downregulation of MACC1 inhibits the viability, invasion and migration and induces apoptosis in esophageal carcinoma cells through the phosphatase and tensin homolog/phosphoinositide 3-kinase/protein kinase B signaling pathway. Oncology Letters, 14(4), 4897–4905. https://doi.org/10.3892/ol.2017.6790.CrossRefPubMedPubMedCentral

97.

Fukumoto, S., Hsieh, C. M., Maemura, K., Layne, M. D., Yet, S. F., Lee, K. H., et al. (2001). Akt participation in the Wnt signaling pathway through Dishevelled. The Journal of Biological Chemistry, 276(20), 17479–17483. https://doi.org/10.1074/jbc.C000880200.CrossRefPubMed

98.

Fang, D., Hawke, D., Zheng, Y., Xia, Y., Meisenhelder, J., Nika, H., et al. (2007). Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. The Journal of Biological Chemistry, 282(15), 11221–11229. https://doi.org/10.1074/jbc.M611871200.CrossRefPubMedPubMedCentral

99.

Lee, G., Goretsky, T., Managlia, E., Dirisina, R., Singh, A. P., Brown, J. B., et al. (2010). phosphoinositide 3-kinase signaling mediates β-Catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology, 139, 869–881.e869. https://doi.org/10.1053/j.gastro.2010.05.037.CrossRefPubMedPubMedCentral

100.

Stein, U., Arlt, F., Walther, W., Smith, J., Waldman, T., Harris, E. D., et al. (2006). The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology, 131(5), 1486–1500. https://doi.org/10.1053/j.gastro.2006.08.041.CrossRefPubMed

101.

Klaus, A., & Birchmeier, W. (2008). Wnt signalling and its impact on development and cancer. Nature Reviews Cancer, 8, 387–398. https://doi.org/10.1038/nrc2389.CrossRefPubMed

102.

Gonzalez, D. M., & Medici, D. (2014). Signaling mechanisms of the epithelial-mesenchymal transition. Science Signaling, 7, re8. https://doi.org/10.1126/scisignal.2005189.CrossRefPubMedPubMedCentral

103.

Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003). Met, metastasis, motility and more. Nature Reviews. Molecular Cell Biology, 4(12), 915–925. https://doi.org/10.1038/nrm1261.CrossRefPubMed

104.

Zhang, W., & Liu, H. T. (2002). MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Research, 12(1), 9–18. https://doi.org/10.1038/sj.cr.7290105.CrossRefPubMed

105.

Tan, N. Y., & Khachigian, L. M. (2009). Sp1 phosphorylation and its regulation of gene transcription. Molecular and Cell Biology, 29(10), 2483–2488. https://doi.org/10.1128/MCB.01828-08.CrossRef

106.

Wang, H., Wang, H. S., Zhou, B. H., Li, C. L., Zhang, F., Wang, X. F., et al. (2013). Epithelial-mesenchymal transition (EMT) induced by TNF-alpha requires AKT/GSK-3beta-mediated stabilization of snail in colorectal cancer. PLoS ONE, 8(2), e56664. https://doi.org/10.1371/journal.pone.0056664.CrossRefPubMedPubMedCentral

107.

Dong, G., Wang, M., Gu, G., Li, S., Sun, X., Li, Z., et al. (2018). MACC1 and HGF are associated with survival in patients with gastric cancer. Oncology Letters, 15(3), 3207–3213. https://doi.org/10.3892/ol.2017.7710.CrossRefPubMed

108.

Lichtenberger, B. M., Tan, P. K., Niederleithner, H., Ferrara, N., Petzelbauer, P., & Sibilia, M. (2010). Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell, 140(2), 268–279. https://doi.org/10.1016/j.cell.2009.12.046.CrossRefPubMed

109.

Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews Cancer, 9, 153–166. https://doi.org/10.1038/nrc2602.CrossRefPubMed

110.

Meyer, N., & Penn, L. Z. (2008). Reflecting on 25 years with MYC. Nature Reviews Cancer, 8, 976–990. https://doi.org/10.1038/nrc2231.CrossRefPubMed

111.

Song, M. S., Salmena, L., & Pandolfi, P. P. (2012). The functions and regulation of the PTEN tumour suppressor. Nature Reviews. Molecular Cell Biology, 13(5), 283–296. https://doi.org/10.1038/nrm3330.CrossRefPubMed

112.

Sun, L., Li, G., Dai, B., Tan, W., Zhao, H., Li, X., et al. (2015). Silence of MACC1 expression by RNA interference inhibits proliferation, invasion and metastasis, and promotes apoptosis in U251 human malignant glioma cells. Molecular Medicine Reports, 12(3), 3423–3431. https://doi.org/10.3892/mmr.2015.3886.CrossRefPubMedPubMedCentral

113.

Wang, L., Wu, Y., Lin, L., Liu, P., Huang, H., Liao, W., et al. (2013). Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion. International Journal of Cancer, 133(6), 1419–1430. https://doi.org/10.1002/ijc.28140.CrossRefPubMed

114.

Schmid, F., Wang, Q., Huska, M. R., Andrade-Navarro, M. A., Lemm, M., Fichtner, I., et al. (2016). SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival. Oncogene, 35(46), 5942–5952. https://doi.org/10.1038/onc.2015.451.CrossRefPubMed

115.

Yao, Y., Dou, C., Lu, Z., Zheng, X., & Liu, Q. (2015). MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway. Cellular Physiology and Biochemistry, 35(3), 983–996. https://doi.org/10.1159/000369754.CrossRefPubMed

116.

Chen, X. P., Ren, X. P., Lan, J. Y., Chen, Y. G., & Shen, Z. J. (2014). Analysis of HGF, MACC1, C-met and apoptosis-related genes in cervical carcinoma mice. Molecular Biology Reports, 41(3), 1247–1256. https://doi.org/10.1007/s11033-013-2969-5.CrossRefPubMed

117.

Radhakrishnan, H., Ilm, K., Walther, W., Shirasawa, S., Sasazuki, T., Daniel, P. T., et al. (2017). MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers. Cancer Letters, 403, 231–245. https://doi.org/10.1016/j.canlet.2017.06.020.CrossRefPubMed

118.

Zhang, X. K., Zhang, L. X., Jia, C. Y., Sun, H. M., Zou, Q. G., Wang, Z., et al. (2017). MACC1 overexpression induces cisplatin resistance in lung adenocarcinoma A549 cells by activating c-Met/Akt pathway. International Journal of Clinical and Experimental Medicine, 10(8), 11778–11786.

119.

Modiano, J. F., & Bellgrau, D. (2016). Fas ligand based immunotherapy: A potent and effective neoadjuvant with checkpoint inhibitor properties, or a systemically toxic promoter of tumor growth? Discovery Medicine, 21, 109–116.PubMed

120.

Jazirehi, A. R., Lim, A., & Dinh, T. (2016). PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. American Journal of Cancer Research, 6(10), 2117–2128.PubMedPubMedCentral

121.

Erreni, M., Mantovani, A., & Allavena, P. (2011). Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenvironment, 4(2), 141–154. https://doi.org/10.1007/s12307-010-0052-5.CrossRefPubMed

122.

Jedinak, A., Dudhgaonkar, S., & Sliva, D. (2010). Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology, 215, 242–249. https://doi.org/10.1016/j.imbio.2009.03.004.CrossRefPubMed

123.

de Aquino, M. T. P., Malhotra, A., Mishra, M. K., & Shanker, A. (2015). Challenges and future perspectives of T cell immunotherapy in cancer. Immunology Letters, 166, 117–133. https://doi.org/10.1016/j.imlet.2015.05.018.CrossRefPubMedPubMedCentral

124.

Balkwill, F., Charles, K. A., & Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7(3), 211–217. https://doi.org/10.1016/j.ccr.2005.02.013.CrossRefPubMed

125.

Dulai, P. S., Sandborn, W. J., & Gupta, S. (2016). Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management. Cancer Prevention Research (Philadelphia, Pa.), 9(12), 887–894. https://doi.org/10.1158/1940-6207.CAPR-16-0124.CrossRef

126.

Elding, H., Lau, W., Swallow, D. M., & Maniatis, N. (2013). Refinement in localization and identification of gene regions associated with Crohn disease. American Journal of Human Genetics, 92(1), 107–113. https://doi.org/10.1016/j.ajhg.2012.11.004.CrossRefPubMedPubMedCentral

127.

Harpaz, N., Taboada, S., Mabel Ko, H., Yu, J., Yang, Q., Xu, H., et al. (2014). Expression of MACC1 and MET in inflammatory bowel disease-associated colonic neoplasia. Inflammatory Bowel Diseases, 20, 703–711. https://doi.org/10.1097/01.MIB.0000442679.39804.48.CrossRefPubMed

128.

Low-Marchelli, J. M., Ardi, V. C., Vizcarra, E. A., van Rooijen, N., Quigley, J. P., & Yang, J. (2013). Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Research, 73(2), 662–671. https://doi.org/10.1158/0008-5472.CAN-12-0653.CrossRefPubMedPubMedCentral

129.

Ilm, K., Kemmner, W., Osterland, M., Burock, S., Koch, G., Herrmann, P., et al. (2015). High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients. Molecular Cancer, 14, 38. https://doi.org/10.1186/s12943-015-0316-2.CrossRefPubMedPubMedCentral

130.

Lang, A. H., Geller-Rhomberg, S., Winder, T., Stark, N., Gasser, K., Hartmann, B., et al. (2012). A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. BMC Cancer, 12, 20. https://doi.org/10.1186/1471-2407-12-20.CrossRefPubMedPubMedCentral

131.

Schmid, F., Burock, S., Klockmeier, K., Schlag, P. M., & Stein, U. (2012). SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer. Molecular Cancer, 11, 49. https://doi.org/10.1186/1476-4598-11-49.CrossRefPubMedPubMedCentral

132.

Horvat, M., Potocnik, U., Repnik, K., Kavalar, R., Zadnik, V., Potrc, S., et al. (2017). Single nucleotide polymorphisms in genes MACC1, RAD18, MMP7 and SDF-1a as prognostic factors in resectable colorectal cancer. Radiology and Oncology, 51(2), 151–159. https://doi.org/10.1515/raon-2016-0043.CrossRefPubMed

133.

Dai, Z.-J., Liu, X.-H., Kang, H.-F., Wang, X.-J., Jin, T.-B., Zhang, S.-Q., et al. (2016). Genetic variation in metastasis-associated in colon cancer-1 and the risk of breast cancer among the Chinese Han population: a STROBE-compliant observational study. Medicine, 95, e2801. https://doi.org/10.1097/MD.0000000000002801.CrossRefPubMedPubMedCentral

134.

Zheng, Z., Gao, S., Yang, Z., Xie, H., Zhang, C., Lin, B., et al. (2014). Single nucleotide polymorphisms in the metastasis-associated in colon cancer-1 gene predict the recurrence of hepatocellular carcinoma after transplantation. International Journal of Medical Sciences, 11(2), 142–150. https://doi.org/10.7150/ijms.7142.CrossRefPubMedPubMedCentral

135.

Galimi, F., Torti, D., Sassi, F., Isella, C., Corà, D., Gastaldi, S., et al. (2011). Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clinical Cancer Research, 17, 3146–3156. https://doi.org/10.1158/1078-0432.CCR-10-3377.CrossRefPubMed

136.

Fabris, L., Cadamuro, M., Libbrecht, L., Raynaud, P., Spirli, C., Fiorotto, R., et al. (2008). Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. Hepatology, 47(2), 719–728. https://doi.org/10.1002/hep.22015.CrossRefPubMed

137.

Sleeman, J. P., & Thiele, W. (2009). Tumor metastasis and the lymphatic vasculature. International Journal of Cancer, 125(12), 2747–2756. https://doi.org/10.1002/ijc.24702.CrossRefPubMed

138.

Alishekevitz, D., Gingis-Velitski, S., Kaidar-Person, O., Gutter-Kapon, L., Scherer, S. D., Raviv, Z., et al. (2016). Macrophage-induced lymphangiogenesis and metastasis following paclitaxel chemotherapy is regulated by VEGFR3. Cell Reports, 17(5), 1344–1356. https://doi.org/10.1016/j.celrep.2016.09.083.CrossRefPubMedPubMedCentral

139.

Lin, L., Huang, H., Liao, W., Ma, H., Liu, J., Wang, L., et al. (2015). MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect. Oncogene, 34(21), 2700–2710. https://doi.org/10.1038/onc.2014.204.CrossRefPubMed

140.

Liu, J., Pan, C., Guo, L., Wu, M., Guo, J., Peng, S., et al. (2016). A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway. Journal of Hematology & Oncology, 9(1), 76. https://doi.org/10.1186/s13045-016-0302-1.CrossRef

141.

Ji, D., Lu, Z. T., Li, Y. Q., Liang, Z. Y., Zhang, P. F., Li, C., et al. (2014). MACC1 expression correlates with PFKFB2 and survival in hepatocellular carcinoma. Asian Pacific Journal of Cancer Prevention, 15, 999–1003. https://doi.org/10.7314/APJCP.2014.15.2.999.CrossRefPubMed

142.

Li, Y., Lu, Z., Liang, Z., Ji, D., Zhang, P., Liu, Q., et al. (2015). Metastasis-associated in colon cancer-1 is associated with poor prognosis in hepatocellular carcinoma, partly by promoting proliferation through enhanced glucose metabolism. Molecular Medicine Reports, 12, 426–434. https://doi.org/10.3892/mmr.2015.3416.CrossRefPubMed

143.

Duan, J., Sun, L., Zhao, L., Liao, W. W., Liao, Y., Duan Jiangman, S. L., Liang, Z., Liao, W., Jing, L., Liao, Y., & Liao, W. (2014). Participation of metastasis-associated in colon cancer-1 gene on lipogenesis and chemoresistance of gastric cancer. Journal of Clinical Oncology, 32, e15026.CrossRef

144.

Shay, J. W., & Wright, W. E. (2000). Hayflick, his limit, and cellular ageing. Nature Reviews. Molecular Cell Biology, 1(1), 72–76. https://doi.org/10.1038/35036093.CrossRefPubMed

145.

Blasco, M. A. (2005). Telomeres and human disease: ageing, cancer and beyond. Nature Reviews. Genetics, 6(8), 611–622. https://doi.org/10.1038/nrg1656.CrossRefPubMed

146.

Cong, Y., & Shay, J. W. (2008). Actions of human telomerase beyond telomeres. Cell Research, 18(7), 725–732. https://doi.org/10.1038/cr.2008.74.CrossRefPubMed

147.

Hannen, R., & Bartsch, J. W. (2018). Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Letters, 592(12), 2023–2031. https://doi.org/10.1002/1873-3468.13084.CrossRefPubMed

148.

Park, J. I., Venteicher, A. S., Hong, J. Y., Choi, J., Jun, S., Shkreli, M., et al. (2009). Telomerase modulates Wnt signalling by association with target gene chromatin. Nature, 460(7251), 66–72. https://doi.org/10.1038/nature08137.CrossRefPubMedPubMedCentral

149.

Liu, Z., Li, Q., Li, K., Chen, L., Li, W., Hou, M., et al. (2013). Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene, 32(36), 4203–4213. https://doi.org/10.1038/onc.2012.441.CrossRefPubMed

150.

Yu, L., Liu, S., Zhang, C., Zhang, B., Simoes, B. M., Eyre, R., et al. (2013). Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. Oncotarget, 4(12), 2326–2338. https://doi.org/10.18632/oncotarget.1554.CrossRefPubMedPubMedCentral

151.

Zhang, K., Guo, Y., Wang, X., Zhao, H., Ji, Z., Cheng, C., et al. (2017). WNT/beta-Catenin directs self-renewal symmetric cell division of hTERT(high) prostate cancer stem cells. Cancer Research, 77(9), 2534–2547. https://doi.org/10.1158/0008-5472.CAN-16-1887.CrossRefPubMed

152.

Zhou, L., Yu, L., Zhu, B., Wu, S., Song, W., Gong, X., et al. (2016). Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer. BMC Cancer, 16(1), 876. https://doi.org/10.1186/s12885-016-2903-z.CrossRefPubMedPubMedCentral

153.

Evran, E., Sahin, H., Akbas, K., Cigdem, S., & Gunduz, E. (2016). Investigation of MACC1 gene expression in head and neck cancer and cancer stem cells. Clinical and Investigative Medicine, 39(6), 27506. https://doi.org/10.25011/cim.v39i6.27506.CrossRefPubMed

154.

Yu, L., Zhu, B., Wu, S., Zhou, L., Song, W., Gong, X., et al. (2017). Evaluation of the correlation of vasculogenic mimicry, ALDH1, KiSS-1, and MACC1 in the prediction of metastasis and prognosis in ovarian carcinoma. Diagnostic Pathology, 12(1), 23. https://doi.org/10.1186/s13000-017-0612-9.CrossRefPubMedPubMedCentral

155.

Nair, R. M., Balla, M. M., Khan, I., Kalathur, R. K. R., Kondaiah, P., & Vemuganti, G. K. (2017). In vitro characterization of CD133(lo) cancer stem cells in retinoblastoma Y79 cell line. BMC Cancer, 17(1), 779. https://doi.org/10.1186/s12885-017-3750-2.CrossRefPubMedPubMedCentral

156.

Juneja, M., Kobelt, D., Walther, W., Voss, C., Smith, J., Specker, E., et al. (2017). Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1. PLoS Biology, 15(6), e2000784. https://doi.org/10.1371/journal.pbio.2000784.CrossRefPubMedPubMedCentral

157.

Melvin, V. S., Feng, W., Hernandez-Lagunas, L., Artinger, K. B., & Williams, T. (2013). A morpholino-based screen to identify novel genes involved in craniofacial morphogenesis. Developmental Dynamics, 242(7), 817–831. https://doi.org/10.1002/dvdy.23969.CrossRefPubMedPubMedCentral

Titel: MACC1—the first decade of a key metastasis molecule from gene discovery to clinical translation
verfasst von: Harikrishnan Radhakrishnan
Wolfgang Walther
Fabian Zincke
Dennis Kobelt
Francesca Imbastari
Müge Erdem
Benedikt Kortüm
Mathias Dahlmann
Ulrike Stein
Publikationsdatum: 03.01.2019
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2018
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9771-8

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

MACC1—the first decade of a key metastasis molecule from gene discovery to clinical translation

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Pleiotropic effects of moonlighting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in cancer progression, invasiveness, and metastases

Cross-talk between lung cancer and bones results in neutrophils that promote tumor progression

Developing TRAIL/TRAIL death receptor-based cancer therapies

From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma

A contemporary review of male breast cancer: current evidence and unanswered questions

Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie